Praxis Precision Medicines Dirección
Dirección controles de criterios 4/4
El CEO de Praxis Precision Medicines es Marcio De'Souza , nombrado en Apr 2020, tiene una permanencia de 4.58 años. compensación anual total es $2.12M, compuesta por 29.5% salario y 70.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.089% de las acciones de la empresa, por valor de $1.27M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 3 años, respectivamente.
Información clave
Marcio De'Souza
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 29.5% |
| Permanencia del CEO | 4.6yrs |
| Participación del CEO | 0.09% |
| Permanencia media de la dirección | 3.9yrs |
| Promedio de permanencia en la Junta Directiva | 3yrs |
Actualizaciones recientes de la dirección
Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$151m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$625k | -US$123m |
| Sep 30 2023 | n/a | n/a | -US$138m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$183m |
| Dec 31 2022 | US$6m | US$625k | -US$214m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$11m | US$571k | -US$167m |
| Sep 30 2021 | n/a | n/a | -US$135m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$12m | US$385k | -US$70m |
Compensación vs. Mercado: La compensación total de Marcio($USD2.12M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.42M).
Compensación vs. Ingresos: La compensación de Marcio ha sido consistente con los resultados de la empresa en el último año.
CEO
Marcio De'Souza (45 yo)
4.6yrs
Permanencia
US$2,120,512
Compensación
Mr. Marcio Silva De'Souza has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in April 20...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.6yrs | US$2.12m | 0.089% $ 1.3m | |
| CFO & Treasurer | 3.5yrs | US$1.02m | 0.019% $ 272.1k | |
| General Counsel & Secretary | 4.4yrs | US$843.11k | 0.013% $ 180.7k | |
| Co-Founder & Chief Scientific Officer | 6.8yrs | sin datos | sin datos | |
| VP of Finance & Principal Accounting Officer | no data | sin datos | 0.0085% $ 122.2k | |
| Chief Technical Operations Officer | 2.9yrs | sin datos | sin datos | |
| VP of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Chief People Officer | 3.9yrs | sin datos | 0.016% $ 225.5k | |
| Chief Regulatory & Quality Officer | 4.2yrs | sin datos | sin datos | |
| Chief Business Officer | 2.9yrs | sin datos | sin datos | |
| Chief of Staff | 2.7yrs | sin datos | sin datos |
3.9yrs
Permanencia media
45yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PRAX se considera experimentado (3.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.6yrs | US$2.12m | 0.089% $ 1.3m | |
| Independent Director | 7.9yrs | US$79.28k | 0.010% $ 145.9k | |
| Independent Chairman of the Board | 4.2yrs | US$104.37k | 0.027% $ 384.4k | |
| Independent Director | 5.7yrs | US$82.87k | 0.0010% $ 14.5k | |
| Independent Director | 3.6yrs | US$76.28k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$78.87k | 0.0052% $ 74.2k | |
| Independent Director | 3.6yrs | US$72.87k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Chairman of the Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos |
3.0yrs
Permanencia media
68yo
Promedio de edad
Junta con experiencia: La junta directiva de PRAX se considera experimentada (3 años de antigüedad promedio).